Empagliflozin, a diabetes pharmacological agent that works through the inhibition of sodium-glucose cotransporter-2, was been reported to increase adiponectin levels in mice through an unknown mechanism (147, 148). This evidence concerns the gene SLC5A2 and diabetes mellitus.